We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sounds like a perfectly reasonable explanation of why something can slip with no change to the outcome, so no failure of 4D.
Hi SL, SJ & LM,
hxxps://imgur.com/a/vR055q5
LM you got it.
You are aware that the Keytruda trial is taking place at 4 different locations in the US?
The Phase 1 of the Imperial study was completed last year and we are awaiting an update for when the second part will start
I don't know how you construe my post as supporting a short - each to their own I suppose. I am here for the long haul even though it has not been pretty for quite a while.
First ever post. You guys seem to be really panicking about your short positions. Some of these are so laughable
So very desperate
I am not surprised or worried that MRx0518 / Keytruda slips into Q1 2022, in fact, I am surprised that the study has been able to keep going through Covid. I am sure a number of you are fully aware of what is required of a candidate who agrees to participate in a trial, others may not be. In the case of the MRx0518 phase1 trial with Imperial College it required a pre-examination visit lasting approx 4 hrs, then dosing and a further 6 follow up hospital visits for check ups Blood, Urine and Poo samples. Post surgery your are required to attend another 4 check up sessions over the next two years.
I personally pulled out after the initial preexam session as everything took too long - you are treated as any other patient in the NHS and join the same queues for bloods, ECG etc; prior to this trial I had agreed to give additional biopsy samples for testing, (the prelims for this) got me kicked off a scheduled biopsy slot, spending an additional afternoon in hospital.
7 visits to a hospital during Covid did not strike me as a great idea given I was being classed as "extremely vulnerable" by the NHS. Drug companies outsource the trials to a third party testing company who in turn effectively outsource it to the NHS - so it is pretty difficult for the likes of 4D to completely control the schedule.
My trial commencement was Feb 2020 and at that point I was not invested in 4D Pharma, had I been invested at that time I still would have dropped out given the covid risk.